Cytokinetics, Inc. (NASDAQ: CYTK), Molina Healthcare, Inc. (NYSE: MOH), Synopsys, Inc. (NASDAQ: SNPS), and WEBTOON Entertainment Inc. (NASDAQ: WBTN) are currently under investigation by Grabar Law Office regarding allegations of potential breaches of fiduciary duty by their respective officers and directors. Shareholders who purchased shares of these companies before specific dates may have the opportunity to seek corporate reforms, recover funds, and receive court-approved incentive awards at no cost to themselves.
Allegations Against Cytokinetics
The investigation into Cytokinetics centers around claims that its executives made materially false and misleading statements. A federal securities fraud class action complaint alleges that on March 10, 2025, the company revealed that the U.S. Food and Drug Administration (FDA) would not hold an advisory committee meeting for its New Drug Application (NDA) for aficamten. Following this, on May 1, 2025, Cytokinetics disclosed that the FDA extended the Prescription Drug User Fee Act action date for aficamten’s NDA from September 26, 2025, to December 26, 2025, after the company failed to include a Risk Evaluation and Mitigation Strategy (REMS) in its original filing.
On May 6, 2025, Chief Executive Officer Robert I. Blum acknowledged that multiple pre-NDA meetings had taken place with the FDA regarding safety monitoring and risk mitigation, yet the NDA was submitted without a REMS. These delayed disclosures and misleading statements have reportedly caused significant harm to the company and its shareholders.
Molina Healthcare’s Financial Misstatements
Similarly, Grabar Law Office is investigating Molina Healthcare, which is accused of failing to disclose adverse facts related to its “medical cost trend assumptions.” The allegations state that the company experienced a dislocation between premium rates and medical costs, and that its financial guidance for fiscal year 2025 was likely to be cut due to reliance on a lack of utilization in behavioral health and other key services.
If you purchased shares of Molina Healthcare before February 5, 2025, you may be eligible for corporate reforms and other benefits.
Concerns Surrounding Synopsys
The investigation into Synopsys follows allegations that the company misled investors regarding its acquisition of Ansys, Inc. (NASDAQ: ANSS). On March 14, 2024, Synopsys filed a registration statement with the SEC for the acquisition, which was approved on April 17, 2024. The acquisition materials promised ANSYS shareholders $197.00 in cash and 0.345 shares of Synopsys common stock for each share held.
The complaint alleges that Synopsys’s financial performance was artificially inflated, failing to disclose crucial facts about its business practices that were negatively affecting its revenue. Following a disappointing Q3 2025 report on September 9, 2025, Synopsys’s stock fell by 35.8%, from $604.37 to $387.78 per share, wiping out billions in market capitalization.
WEBTOON Entertainment’s Legal Struggles
WEBTOON Entertainment is facing its own challenges, as a class action complaint has survived a motion to dismiss from its executives. The U.S. District Court for the Central District of California ruled that claims regarding misleading statements about its Monthly Active Users (MAU) during its June 27, 2024 IPO could proceed. The court found that the allegations of misleading risk disclosures were plausible, allowing shareholders to pursue their claims.
If you purchased shares of WEBTOON on or shortly after its IPO, you can explore options for corporate reforms and other remedies.
For more information regarding your rights as a shareholder of these companies, contact Joshua H. Grabar at [email protected] or by phone at 267-507-6085. Each investigation offers shareholders a chance to seek justice and accountability from the companies in which they have invested.
